Is Survodutide Better Than Ozempic or Zepbound?
Survodutide's first Phase 3 trial in type 2 diabetes just posted up to 13% weight loss over 76 weeks. That clears Ozempic and lands inside Zepbound's range. The catch: the comparisons are all cross-trial, nearly one in five patients quit for side effects, and no regulator has approved it. For now, the drug that will help you this year is still the one your pharmacy already stocks.
SYNCHRONIZE-2, published October 1 in the New England Journal of Medicine, tested survodutide in 755 adults with type 2 diabetes over 76 weeks. On the higher dose, patients lost 13.1% of body weight versus 3.1% on placebo. Waists shrank about 11 cm, and nearly a third of patients reached a normal HbA1c. For a diabetes trial, those are strong numbers. They're also the first Phase 3 evidence that a dual GLP-1 and glucagon agonist works at scale.
Why the glucagon piece matters
Survodutide hits two receptors instead of one. The GLP-1 half does what Ozempic and Wegovy do: it blunts appetite and slows gastric emptying. The glucagon half, which Ozempic doesn't touch, raises energy expenditure and mobilizes liver fat. Tirzepatide (Zepbound, Mounjaro) also hits two receptors, but it pairs GLP-1 with GIP, not glucagon. SYNCHRONIZE-2 is the first large diabetes trial to show the glucagon pairing can reach the same weight-loss ceiling the GIP pairing already set.
An earlier 16-week Phase 2 trial hinted at this: at 1.8 mg weekly or higher, survodutide beat open-label semaglutide 1.0 mg on weight loss and matched it on HbA1c. SYNCHRONIZE-2 turns that hint into Phase 3 evidence.
How it stacks up against Ozempic and Zepbound
The headline weight loss clears semaglutide and lands inside tirzepatide's range. HbA1c looks competitive. But every comparison below is cross-trial, meaning different populations, placebos, and durations. None of these drugs has been tested against another in a head-to-head Phase 3 trial.
| Drug (dose, trial) | Duration | Mean weight loss vs placebo | HbA1c reduction | Approval status |
|---|---|---|---|---|
| Survodutide 3.6 or 6.0 mg (SYNCHRONIZE-2) | 76 weeks | Up to 13.1% vs 3.1% | From 7.4% baseline | Not approved |
| Semaglutide 2.4 mg (STEP 2) | 68 weeks | 9.6% vs 3.4% | 1.6 points, from 8.1% | Approved |
| Tirzepatide 10 or 15 mg (SURMOUNT-2) | About 2 points | Approved |
On the numbers alone, survodutide is in the conversation. But cross-trial math is the weakest form of drug comparison, and the Phase 2 study that pitted it against semaglutide was short and used a sub-maximal semaglutide dose. What this trial supports is that the ceiling has been matched, not clearly beaten.
Three gaps that keep it off the switch list
First, tolerability. In SYNCHRONIZE-2, 18% of patients on survodutide stopped the drug for side effects. Nausea, vomiting, diarrhea, and constipation drove most of it. That discontinuation rate runs higher than what semaglutide and tirzepatide have shown in their diabetes Phase 3 trials.
Second, hard outcomes. GLP-1 drugs cut major cardiac events by roughly 12% to 14% across a decade of large outcomes trials. Survodutide's own outcomes trial, SYNCHRONIZE-CVOT, has enrolled 5,508 adults with cardiovascular or kidney risk and is still running. Until it reports, there's no evidence that this drug matches the GLP-1 class on heart attacks, strokes, or death.
Third, availability. Survodutide isn't approved for diabetes or obesity in any country. The FDA has granted Fast Track status and a separate Breakthrough designation for fatty liver disease, and the EMA added it to its priority medicines scheme. None of that is approval. If you want a dual-receptor shot now, tirzepatide is the one you can actually get.
What to do while we wait
If you have type 2 diabetes and are weighing a GLP-1, the practical answer hasn't changed. Semaglutide and tirzepatide are approved, available, and backed by cardiovascular outcomes data survodutide doesn't yet have. Starting one of them now and seeing whether you tolerate it is the choice with the most behind it.
Weight regain is the other reality. Across semaglutide and tirzepatide studies, people regained 50% to 68% of their lost weight within a year of stopping. The same pattern will almost certainly show up with survodutide. These drugs work for as long as you take them.
Survodutide's 13% is the first Phase 3 proof that adding glucagon to GLP-1 can hit the top of the diabetes weight-loss range. Until a head-to-head trial, a cardiovascular readout, and an approval arrive, it belongs on the watch list, not the switch list.